Ana Luisa Muñoz , William Hernando Merchán , Ana Luiza Resende Pires , Ângela Maria Moraes , Lina Andrea Gómez
{"title":"富血小板血浆凝胶和壳聚糖和海藻酸盐生物相容性膜对静脉慢性溃疡的生物刺激:一项初步研究","authors":"Ana Luisa Muñoz , William Hernando Merchán , Ana Luiza Resende Pires , Ângela Maria Moraes , Lina Andrea Gómez","doi":"10.1016/j.wndm.2019.100161","DOIUrl":null,"url":null,"abstract":"<div><p>Venous ulcers are a common disease caused by circulatory insufficiency, having as characteristics slow healing and therefore a difficult treatment. Consequently, this disease has a high impact at personal, professional and social levels, representing large costs for both patients and healthcare system. The aim of the present pilot study was to evaluate the effectiveness of an alternative treatment for this specific type of wound, based on the use of autologous platelet-rich plasma gel (PRP) combined with biocompatible porous membranes produced with the polysaccharides chitosan (C) and alginate (A). The applicability, security and healing efficacy of this treatment was evaluated in four patients suffering from venous ulcers with an at least 6-month of evolution that did not heal after conventional treatments. The clinical evolution analysis during the treatment was performed by periodic measurement of the lesions area for an average of 5.4 months. The results attained showed that the use of this treatment led to completed reduction in the ulcers area as well as to pain decrease. Hence, the combination between autologous PRP gel and chitosan-alginate (CA) porous membranes could be a useful alternative to treat chronic skin ulcers in humans.</p></div>","PeriodicalId":38278,"journal":{"name":"Wound Medicine","volume":"26 1","pages":"Article 100161"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.wndm.2019.100161","citationCount":"3","resultStr":"{\"title\":\"Biostimulation of venous chronic ulcers with platelet-rich plasma gel and biocompatible membranes of chitosan and alginate: A pilot study\",\"authors\":\"Ana Luisa Muñoz , William Hernando Merchán , Ana Luiza Resende Pires , Ângela Maria Moraes , Lina Andrea Gómez\",\"doi\":\"10.1016/j.wndm.2019.100161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Venous ulcers are a common disease caused by circulatory insufficiency, having as characteristics slow healing and therefore a difficult treatment. Consequently, this disease has a high impact at personal, professional and social levels, representing large costs for both patients and healthcare system. The aim of the present pilot study was to evaluate the effectiveness of an alternative treatment for this specific type of wound, based on the use of autologous platelet-rich plasma gel (PRP) combined with biocompatible porous membranes produced with the polysaccharides chitosan (C) and alginate (A). The applicability, security and healing efficacy of this treatment was evaluated in four patients suffering from venous ulcers with an at least 6-month of evolution that did not heal after conventional treatments. The clinical evolution analysis during the treatment was performed by periodic measurement of the lesions area for an average of 5.4 months. The results attained showed that the use of this treatment led to completed reduction in the ulcers area as well as to pain decrease. Hence, the combination between autologous PRP gel and chitosan-alginate (CA) porous membranes could be a useful alternative to treat chronic skin ulcers in humans.</p></div>\",\"PeriodicalId\":38278,\"journal\":{\"name\":\"Wound Medicine\",\"volume\":\"26 1\",\"pages\":\"Article 100161\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.wndm.2019.100161\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Wound Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213909519300114\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wound Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213909519300114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Biostimulation of venous chronic ulcers with platelet-rich plasma gel and biocompatible membranes of chitosan and alginate: A pilot study
Venous ulcers are a common disease caused by circulatory insufficiency, having as characteristics slow healing and therefore a difficult treatment. Consequently, this disease has a high impact at personal, professional and social levels, representing large costs for both patients and healthcare system. The aim of the present pilot study was to evaluate the effectiveness of an alternative treatment for this specific type of wound, based on the use of autologous platelet-rich plasma gel (PRP) combined with biocompatible porous membranes produced with the polysaccharides chitosan (C) and alginate (A). The applicability, security and healing efficacy of this treatment was evaluated in four patients suffering from venous ulcers with an at least 6-month of evolution that did not heal after conventional treatments. The clinical evolution analysis during the treatment was performed by periodic measurement of the lesions area for an average of 5.4 months. The results attained showed that the use of this treatment led to completed reduction in the ulcers area as well as to pain decrease. Hence, the combination between autologous PRP gel and chitosan-alginate (CA) porous membranes could be a useful alternative to treat chronic skin ulcers in humans.